SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-006591
Filing Date
2021-02-04
Accepted
2021-02-03 20:27:03
Documents
2
Period of Report
2021-02-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea134530-8k_ocuphire.htm 8-K 39889
2 FORM OF WAIVER AGREEMENT, DATED AS OF FEBRUARY 3, 2021, BY AND BETWEEN OCUPHIRE ea134530ex4-1_ocuphire.htm EX-4.1 152585
  Complete submission text file 0001213900-21-006591.txt   193838
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

IRS No.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 21588335
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences